Accretion Pharmaceuticals FY26: Export-led scale-up lifts revenue to Rs 89.63 crore
Frequently Asked Questions
Total income from operations was 89.63 crore in FY26, up 56.21% year on year from 57.38 crore in FY25.
EBITDA excluding other income was 14.95 crore in FY26 and profit after tax was 9.67 crore.
Based on the dosage form revenue figures, tablets contributed 28.8 crore, oral liquids 20.9 crore, capsules 16.9 crore, external preparations 16.3 crore and oral powders 6.8 crore in FY26.
Total installed capacity is stated as 1635 million units, comprising tablets 1000 million, capsules 450 million, oral liquids 21.75 million bottles, oral powders 153.75 million bottles and pouch, and external preparations 9 million tubes.
The company states it has a direct export network across 30 countries in Africa, Southeast Asia and Latin America, along with domestic presence across more than 16 Indian states.
Key ratios show total debt to equity at 0.2 in FY26. The presentation also states net debt to equity of 0.15 in FY26.
The presentation and management commentary highlight geographic diversification with a shift toward direct exports, new product development, plant modernization, scaling CDMO capabilities, and adding customers while increasing wallet share.
Did your stocks survive the war?
See what broke. See what stood.
Live Q1 Earnings Tracker